日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

The Impact of Multiple Sclerosis on Work Productivity: A Preliminary Look at the North American Registry for Care and Research in Multiple Sclerosis

多发性硬化症对工作效率的影响：北美多发性硬化症护理和研究登记处的初步研究

期刊:NeuroSci
影响因子:2
doi:10.3390/neurosci6030082
Ali, Ahya; Rammohan, Kottil; Halper, June; Livingston, Terrie; Murphy, Sara McCurdy; Patton, Lisa; Wilkerson, Jesse; Mao-Draayer, Yang; On Behalf Of The Narcrms Healthcare Economics Outcomes Research Advisory Group
神经科学
多发性硬化症
发表日期：2025
文献求助 收藏

Identification and management of subclinical disease activity in early multiple sclerosis: a review

早期多发性硬化症亚临床疾病活动的识别与管理：综述

期刊:Journal of Neurology
影响因子:4.6
doi:10.1007/s00415-023-12021-5
Ontaneda, Daniel; Chitnis, Tanuja; Rammohan, Kottil; Obeidat, Ahmed Z
神经科学
多发性硬化症
发表日期：2024
文献求助 收藏

Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment

抗CD20单克隆抗体的关键特征及其在多发性硬化症治疗中的临床意义

期刊:Journal of Neurology
影响因子:4.6
doi:10.1007/s00415-023-12007-3
Delgado, Silvia R; Faissner, Simon; Linker, Ralf A; Rammohan, Kottil
单克隆抗体
神经科学
多发性硬化症
CD20
CD2
发表日期：2024
文献求助 收藏

Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study

CLASSIC-MS 研究 CLARITY/CLARITY Extension 队列中复发型多发性硬化症患者的长期随访：一项回顾性/非回顾性研究

期刊:Multiple Sclerosis Journal
影响因子:5
doi:10.1177/13524585231161494
Giovannoni, Gavin; Boyko, Alexey; Correale, Jorge; Edan, Gilles; Freedman, Mark S; Montalban, Xavier; Rammohan, Kottil; Stefoski, Dusan; Yamout, Bassem; Leist, Thomas; Aydemir, Aida; Borsi, Laszlo; Verdun di Cantogno, Elisabetta
神经科学
多发性硬化症
发表日期：2023
文献求助 收藏

Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies

对接受克拉屈滨片剂或安慰剂治疗的多发性硬化症患者复发频率和严重程度的分析：CLARITY 和 CLARITY Extension 研究

期刊:Multiple Sclerosis Journal
影响因子:5
doi:10.1177/13524585211010294
De Stefano, Nicola; Sormani, Maria Pia; Giovannoni, Gavin; Rammohan, Kottil; Leist, Thomas; Coyle, Patricia K; Dangond, Fernando; Keller, Birgit; Alexandri, Nektaria; Galazka, Andrew
神经科学
多发性硬化症
发表日期：2022
文献求助 收藏

COVID-19 in the pregnant or postpartum MS patient: Symptoms and outcomes

妊娠期或产后多发性硬化症患者感染新冠病毒：症状和结局

期刊:Multiple Sclerosis and Related Disorders
影响因子:2.9
doi:10.1016/j.msard.2022.104028
Salter, Amber; Cross, Anne H; Cutter, Gary R; Fox, Robert J; Li, David K B; Bebo, Bruce; Halper, June; Kanellis, Pamela; Rammohan, Kottil; Newsome, Scott D
新冠
炎症/感染
神经科学
多发性硬化症
微生物学
发表日期：2022
文献求助 收藏

Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis

北美多发性硬化症患者登记研究中与SARS-CoV-2感染相关的结局和风险因素

期刊:Jama Neurology
影响因子:21.3
doi:10.1001/jamaneurol.2021.0688
Salter, Amber; Fox, Robert J; Newsome, Scott D; Halper, June; Li, David K B; Kanellis, Pamela; Costello, Kathleen; Bebo, Bruce; Rammohan, Kottil; Cutter, Gary R; Cross, Anne H
炎症/感染
SARS-CoV-2
神经科学
多发性硬化症
发表日期：2021
文献求助 收藏

COVID-19 in Patients With Neuromyelitis Optica Spectrum Disorders and Myelin Oligodendrocyte Glycoprotein Antibody Disease in North America: From the COViMS Registry

北美地区视神经脊髓炎谱系障碍和髓鞘少突胶质细胞糖蛋白抗体疾病患者的 COVID-19 情况：来自 COViMS 注册研究

期刊:Neurology-Neuroimmunology & Neuroinflammation
影响因子:7.5
doi:10.1212/NXI.0000000000001057
Newsome, Scott D; Cross, Anne H; Fox, Robert J; Halper, June; Kanellis, Pamela; Bebo, Bruce; Li, David; Cutter, Gary R; Rammohan, Kottil W; Salter, Amber
神经科学
细胞生物学
多发性硬化症
胶质细胞
发表日期：2021
文献求助 收藏

Expert Perspectives on COVID-19 Vaccination for People Living with Multiple Sclerosis

专家对多发性硬化症患者接种新冠疫苗的看法

期刊:Neurology and Therapy
影响因子:4.8
doi:10.1007/s40120-021-00266-z
Shin, Robert K; Rammohan, Kottil W; Williams, Mitzi J
微生物学
新冠
神经科学
多发性硬化症
发表日期：2021
文献求助 收藏

Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies

采用扩展残疾状态量表评估接受克拉屈滨片 3.5 mg/kg 治疗的复发型多发性硬化症患者的长期疾病稳定性：CLARITY 和 CLARITY 扩展研究的探索性事后分析

期刊:Advances in Therapy
影响因子:4
doi:10.1007/s12325-021-01865-w
Giovannoni, Gavin; Comi, Giancarlo; Rammohan, Kottil; Rieckmann, Peter; Dangond, Fernando; Keller, Birgit; Jack, Dominic; Vermersch, Patrick
神经科学
多发性硬化症
发表日期：2021
文献求助 收藏